within Pharmacolibrary.Drugs.ATC.L;

model L01BC07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 167 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 75 / 1000000,
    adminCount     = 1,
    Vd             = 0.076,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Azacitidine is a nucleoside metabolic inhibitor with antineoplastic activity, primarily used in the treatment of myelodysplastic syndromes (MDS) and certain types of acute myeloid leukemia (AML). It acts by incorporation into DNA and RNA, resulting in cytotoxicity and inhibition of DNA methyltransferase. Azacitidine is approved for clinical use and is currently used in therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with myelodysplastic syndromes after subcutaneous and intravenous administration of azacitidine.</p><h4>References</h4><ol><li><p>Garcia-Manero, G, et al., &amp; Savona, MR (2024). Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. <i>The Lancet. Haematology</i> 11(1) e15–e26. DOI:<a href=&quot;https://doi.org/10.1016/S2352-3026(23)00338-1&quot;>10.1016/S2352-3026(23)00338-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38135371/&quot;>https://pubmed.ncbi.nlm.nih.gov/38135371</a></p></li><li><p>Geissler, K, et al., &amp; Lübbert, M (2024). Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. <i>British journal of haematology</i> 205(5) 1734–1745. DOI:<a href=&quot;https://doi.org/10.1111/bjh.19741&quot;>10.1111/bjh.19741</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39313917/&quot;>https://pubmed.ncbi.nlm.nih.gov/39313917</a></p></li><li><p>DiNardo, CD, et al., &amp; Pollyea, DA (2018). Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. <i>The Lancet. Oncology</i> 19(2) 216–228. DOI:<a href=&quot;https://doi.org/10.1016/S1470-2045(18)30010-X&quot;>10.1016/S1470-2045(18)30010-X</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29339097/&quot;>https://pubmed.ncbi.nlm.nih.gov/29339097</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01BC07;
